Cipla USA, Inc. recalls
12 recall notices naming Cipla USA, Inc. since January 2025, in United States. The most recent was published 14 Oct 2026.
Latest recalls (12)
- Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral SolutionFDAFailed Impurities/Degradation Specifications
- Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
- Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
- Cipla USA, Inc. recalls Lanreotide InjectionFDALack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
- Cipla USA, Inc. recalls Nilotinib CapsulesFDAFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
- Cipla USA, Inc. recalls Diclofenac Sodium Topical GelFDAFailed PH Specifications
- Cipla USA, Inc. recalls Lanreotide InjectionFDAPresence of Particulate Matter.
- Cipla USA, Inc. recalls Lanthanum Carbonate chewable tabletsFDAFailed stability specifications: Out of specification for hardness test
- Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- Cipla Limited recalls Phytonadione Injectable EmulsionFDAFailed Stability Specifications: Observed OOS results: eg results for colour index
- Cipla USA, Inc. recalls Albuterol SulfateFDAFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at…
- Cipla USA, Inc. recalls Budesonide Inhalation SuspensionFDALack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.